Department of Women's and Children's Health, Division of Obstetrics and Gynecology, Karolinska Institute, Stockholm, Sweden.
Department of Women's and Children's Health, Division of Obstetrics and Gynecology, Karolinska Institute, Stockholm, Sweden.
Am J Obstet Gynecol. 2020 Feb;222(2):172.e1-172.e12. doi: 10.1016/j.ajog.2019.08.042. Epub 2019 Aug 29.
Women treated for high-grade cervical intraepithelial neoplasia (grade 2 or 3) are at elevated risk for developing cervical cancer. Suggested factors identifying women at highest risk for recurrence post-therapeutically include incomplete lesion excision, lesion location, size and severity, older age, treatment modality, and presence of high-risk human papilloma virus after treatment. This question has been intensively investigated over decades, but there is still substantial debate as to which of these factors or combination of factors most accurately predict treatment failure.
In this study, we examine the long-term risk of residual/recurrent high-grade cervical intraepithelial neoplasia among women previously treated for cervical intraepithelial neoplasia 2/3 and how this varies according to margin status (considering also location), as well as comorbidity (conditions assumed to interact with high-risk human papilloma virus acquisition and/or cervical intraepithelial neoplasia progression), posttreatment presence of high-risk human papilloma virus, and other factors.
This prospective study included 991 women with histopathologically confirmed cervical intraepithelial neoplasia 2/3 who underwent conization in 2000-2007. Information on the primary histopathologic finding, treatment modality, comorbidity, age, and high-risk human papilloma virus status during follow-up, and residual/recurrent high-grade cervical intraepithelial neoplasia was obtained from the Swedish National Cervical Screening Registry and medical records. Cumulative incidence of residual/recurrent high-grade cervical intraepithelial neoplasia was plotted on Kaplan-Meier curves, with determinants assessed by Cox regression.
During a median of 10 years and maximum of 16 years of follow-up, 111 patients were diagnosed with residual/recurrent high-grade cervical intraepithelial neoplasia or worse. Women with positive/uncertain margins had a higher risk of residual/recurrent high-grade cervical intraepithelial neoplasia or worse than women with negative margins, adjusting for potential confounders (hazard ratio, 2.67; 95% confidence interval, 1.81-3.93). The risk of residual/recurrent high-grade cervical intraepithelial neoplasia or worse varied by anatomical localization of the margins (endocervical: hazard ratio, 2.72; 95% confidence interval, 1.67-4.41) and both endo- and ectocervical (hazard ratio, 4.98; 95% confidence interval, 2.85-8.71). The risk did not increase significantly when only ectocervical margins were positive or uncertain. The presence of comorbidity (autoimmune disease, human immunodeficiency viral infection, hepatitis B and/or C, malignancy, diabetes, genetic disorder, and/or organ transplant) was also a significant independent predictor of residual/recurrent high-grade cervical intraepithelial neoplasia or worse. In women with positive high-risk human papilloma virus findings during follow-up, the hazard ratio of positive/uncertain margins for recurrent/residual high-grade cervical intraepithelial neoplasia or worse increased significantly compared to that in women with positive high-risk human papilloma virus findings but negative margins.
Patients with incompletely excised cervical intraepithelial neoplasia 2/3 are at increased risk for residual/recurrent high-grade cervical intraepithelial neoplasia or worse. Margin status combined with high-risk human papilloma virus results and consideration of comorbidity may increase the accuracy for predicting treatment failure.
接受高级别宫颈上皮内瘤变(2 级或 3 级)治疗的女性发生宫颈癌的风险增加。确定治疗后复发风险最高的女性的建议因素包括病变切除不完全、病变位置、大小和严重程度、年龄较大、治疗方式以及治疗后高危型人乳头瘤病毒的存在。几十年来,这个问题一直受到深入研究,但对于哪些因素或这些因素的组合最能准确预测治疗失败,仍存在很大争议。
本研究旨在检查先前接受宫颈上皮内瘤变 2/3 治疗的女性中残留/复发高级别宫颈上皮内瘤变的长期风险,以及这种风险如何根据边缘状态(同时考虑位置)以及合并症(假定与高危型人乳头瘤病毒获得和/或宫颈上皮内瘤变进展相互作用的疾病)、治疗后高危型人乳头瘤病毒的存在以及其他因素而变化。
本前瞻性研究纳入了 991 名经组织病理学证实患有宫颈上皮内瘤变 2/3 的女性,她们于 2000-2007 年接受了锥切术。从瑞典国家宫颈筛查登记处和病历中获得了关于原发性组织病理学发现、治疗方式、合并症、年龄以及随访期间高危型人乳头瘤病毒状态的信息,以及残留/复发的高级别宫颈上皮内瘤变。使用 Kaplan-Meier 曲线绘制残留/复发高级别宫颈上皮内瘤变的累积发生率,并通过 Cox 回归评估决定因素。
在中位数为 10 年(最长 16 年)的随访期间,有 111 名患者被诊断为残留/复发高级别宫颈上皮内瘤变或更严重的疾病。与边缘阴性的女性相比,边缘阳性/不确定的女性发生残留/复发高级别宫颈上皮内瘤变或更严重疾病的风险更高,调整了潜在混杂因素(风险比,2.67;95%置信区间,1.81-3.93)。残留/复发高级别宫颈上皮内瘤变或更严重疾病的风险因边缘的解剖定位而异(宫颈内:风险比,2.72;95%置信区间,1.67-4.41)和宫颈内和宫颈外(风险比,4.98;95%置信区间,2.85-8.71)。仅宫颈外边缘阳性或不确定时,风险不会显著增加。合并症(自身免疫性疾病、人类免疫缺陷病毒感染、乙型肝炎和/或丙型肝炎、恶性肿瘤、糖尿病、遗传疾病和/或器官移植)的存在也是残留/复发高级别宫颈上皮内瘤变或更严重疾病的显著独立预测因素。在随访期间发现高危型人乳头瘤病毒阳性的女性中,与高危型人乳头瘤病毒阳性但边缘阴性的女性相比,边缘阳性/不确定的女性发生复发性/残留高级别宫颈上皮内瘤变或更严重疾病的风险比显著增加。
未完全切除的宫颈上皮内瘤变 2/3 的患者发生残留/复发高级别宫颈上皮内瘤变或更严重疾病的风险增加。边缘状态结合高危型人乳头瘤病毒结果和合并症的考虑可能会提高预测治疗失败的准确性。